VYNT-0126 ( DrugBank: - )


1 disease
告示番号疾患名(ページ内リンク)臨床試験数
156レット症候群1

156. レット症候群


臨床試験数 : 44 薬物数 : 61 - (DrugBank : 23) / 標的遺伝子数 : 57 - 標的パスウェイ数 : 83
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT05625568
(ClinicalTrials.gov)
March 20237/11/2022Study of VYNT-0126 in the Treatment of Rett Syndrome in Adult PatientsPhase 2, Double-Blind, Randomized, Placebo-Controlled Clinical Study of VYNT-0126 in the Treatment of Rett Syndrome in Adult Female PatientsRett SyndromeDrug: VYNT-0126;Drug: PlaceboVyant BioNULLNot yet recruiting18 Years45 YearsFemale48Phase 2NULL